Cargando…

Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry

Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat ato...

Descripción completa

Detalles Bibliográficos
Autores principales: ARIËNS, Lieneke F. M., BAKKER, Daphne S., SPEKHORST, Lotte S., VAN DER SCHAFT, Jorien, THIJS, Judith L., HAECK, Inge, FLINTERMAN, Annebeth E., KAMSTEEG, Marijke, SCHUTTELAAR, Marie L. A., DE BRUIN-WELLER, Marjolein S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Society for Publication of Acta Dermato-Venereologica 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425610/
https://www.ncbi.nlm.nih.gov/pubmed/34396421
http://dx.doi.org/10.2340/00015555-3886
_version_ 1784778484832272384
author ARIËNS, Lieneke F. M.
BAKKER, Daphne S.
SPEKHORST, Lotte S.
VAN DER SCHAFT, Jorien
THIJS, Judith L.
HAECK, Inge
FLINTERMAN, Annebeth E.
KAMSTEEG, Marijke
SCHUTTELAAR, Marie L. A.
DE BRUIN-WELLER, Marjolein S.
author_facet ARIËNS, Lieneke F. M.
BAKKER, Daphne S.
SPEKHORST, Lotte S.
VAN DER SCHAFT, Jorien
THIJS, Judith L.
HAECK, Inge
FLINTERMAN, Annebeth E.
KAMSTEEG, Marijke
SCHUTTELAAR, Marie L. A.
DE BRUIN-WELLER, Marjolein S.
author_sort ARIËNS, Lieneke F. M.
collection PubMed
description Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat atopic dermatitis in daily practice. Patients treated with dupilumab participating in the Dutch BioDay Registry reporting employment were included. Absenteeism, presenteeism, and related costs at baseline and during follow-up were calculated using the Work Productivity and Activity Impairment questionnaire. A total of 218 adult patients with moderate-to-severe atopic dermatitis were included. Total work impairment reduced significantly from baseline (35.5%) to week 52 (11.5%), p < 0.001. Median weekly productivity losses reduced significantly from baseline (€379.8 (140.7–780.8)) to week 52 (€0.0 (0.0–211.0), p < 0.001). In this study, dupilumab treatment demonstrated a significant improvement in work productivity and reduction in associated costs in a large cohort of patients with difficult-to-treat atopic dermatitis in daily practice.
format Online
Article
Text
id pubmed-9425610
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Society for Publication of Acta Dermato-Venereologica
record_format MEDLINE/PubMed
spelling pubmed-94256102022-10-20 Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry ARIËNS, Lieneke F. M. BAKKER, Daphne S. SPEKHORST, Lotte S. VAN DER SCHAFT, Jorien THIJS, Judith L. HAECK, Inge FLINTERMAN, Annebeth E. KAMSTEEG, Marijke SCHUTTELAAR, Marie L. A. DE BRUIN-WELLER, Marjolein S. Acta Derm Venereol Clinical Report Dupilumab treatment improves signs, symptoms, and quality of life in patients with moderate-to-severe atopic dermatitis. This study evaluated the impact of dupilumab treatment on absenteeism, presenteeism, and related costs in a large multi-centre cohort of adult patients with difficult-to-treat atopic dermatitis in daily practice. Patients treated with dupilumab participating in the Dutch BioDay Registry reporting employment were included. Absenteeism, presenteeism, and related costs at baseline and during follow-up were calculated using the Work Productivity and Activity Impairment questionnaire. A total of 218 adult patients with moderate-to-severe atopic dermatitis were included. Total work impairment reduced significantly from baseline (35.5%) to week 52 (11.5%), p < 0.001. Median weekly productivity losses reduced significantly from baseline (€379.8 (140.7–780.8)) to week 52 (€0.0 (0.0–211.0), p < 0.001). In this study, dupilumab treatment demonstrated a significant improvement in work productivity and reduction in associated costs in a large cohort of patients with difficult-to-treat atopic dermatitis in daily practice. Society for Publication of Acta Dermato-Venereologica 2021-10-19 /pmc/articles/PMC9425610/ /pubmed/34396421 http://dx.doi.org/10.2340/00015555-3886 Text en © 2021 Acta Dermato-Venereologica https://creativecommons.org/licenses/by-nc/4.0/This is an open access article under the CC BY-NC license
spellingShingle Clinical Report
ARIËNS, Lieneke F. M.
BAKKER, Daphne S.
SPEKHORST, Lotte S.
VAN DER SCHAFT, Jorien
THIJS, Judith L.
HAECK, Inge
FLINTERMAN, Annebeth E.
KAMSTEEG, Marijke
SCHUTTELAAR, Marie L. A.
DE BRUIN-WELLER, Marjolein S.
Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
title Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
title_full Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
title_fullStr Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
title_full_unstemmed Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
title_short Rapid and Sustained Effect of Dupilumab on Work Productivity in Patients with Difficult-to-treat Atopic Dermatitis: Results from the Dutch BioDay Registry
title_sort rapid and sustained effect of dupilumab on work productivity in patients with difficult-to-treat atopic dermatitis: results from the dutch bioday registry
topic Clinical Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9425610/
https://www.ncbi.nlm.nih.gov/pubmed/34396421
http://dx.doi.org/10.2340/00015555-3886
work_keys_str_mv AT arienslienekefm rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry
AT bakkerdaphnes rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry
AT spekhorstlottes rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry
AT vanderschaftjorien rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry
AT thijsjudithl rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry
AT haeckinge rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry
AT flintermanannebethe rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry
AT kamsteegmarijke rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry
AT schuttelaarmariela rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry
AT debruinwellermarjoleins rapidandsustainedeffectofdupilumabonworkproductivityinpatientswithdifficulttotreatatopicdermatitisresultsfromthedutchbiodayregistry